The expression of CD8, Foxp3, and PD-L1 in the tumor microenvironment is regarded as predictors for prognosis and response markers to immunotherapy in melanoma, breast cancer, NSCLC, and gastric cancer (25–27). Here, FOXP3 is linked to breast carcinoma.